Vectalys will attend the ASGCT in Washington

29-04-2016

Vectalys will attend the ASGCT on May 4-7, 2016 in Washington, DC to introduce the next generation of non integrating lentiviral particle for gene and cell therapy applications.
Logo ASGCT 2016

We look forward to sharing with you our new non-integrative MS2-based lentiviral particles for mRNA delivery at the American Society of Gene and Cell Therapy (ASGCT 2016). This innovative particle is a safe and efficient opportunity for gene and cell therapy applications.

The details of the presentation are :
Session Date/Time: Friday May 6, 2016 6:00 PM - 8:00 PM
Session title: RNA Virus Vectors
Room: Exhibit Hall C & B South
Final abstract number: 538

Our staff on site :
Pascale Bouille, CEO of Vectalys,

If you would like to set up an appointment date and time prior to the annual meeting, please contact us at sales@vectalys.com or by phone +33 5 82 99 11 02.

Looking forward to seeing you there!

The Vectalys Team